High serum circulating telopeptide type 1 in multinodular goiter

Hormone and Metabolic Research

Volumn 35, Issue 6, 2003, Pages 377-381

  Loviselli, A ^a   Rizzolo, E ^a   Mastinu, R ^a   Velluzzi, F ^a   Secci, G ^a   Taberlet, A ^a   Mariotti, S ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Nodular Goiter; Subclinical Hyperthyroidism; Telopeptide

Indexed keywords

CARBOXY TERMINAL 1 TELOPEPTIDE; PEPTIDE; SEX HORMONE BINDING GLOBULIN; THYROID HORMONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; NODULAR GOITER; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; GOITER, NODULAR; HUMANS; HYPERTHYROIDISM; MENOPAUSE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; SENSITIVITY AND SPECIFICITY; SEX HORMONE-BINDING GLOBULIN; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0041836265     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41361     Document Type: Article

References (47)

1. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358: 861-865
2. Fatourechi V. Adverse effects of subclinical hyperthyroidism. Lancet 2001; 358: 856-857
3. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001; 345: 512-516
4. Cooper DS. Subclinical thyroid disease: a clinician's perspective. Ann Intern Med 1998; 129: 135-138
5. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Group FtSoOFR. Risk for Fracture in Women with Low Serum Levels of Thyroid-Stimulatin Hormone. Ann Intern Med 2001; 134: 561-568
6. Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-1252
7. Biondi B, Palmieri EA, Fazio S et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85: 4701-4705
8. Ross DS, Ardisson LJ, Meskell MJ. Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. J Clin Endocrinol Metab 1989; 69: 684-688
9. Kasagi K, Kousaka T, Misaki T, Iwata M, Alam MS, Konishi J. Comparison of serum thyrotrophin concentrations determined by a third generation assay in patients with various types of overt and subclinical thyrotoxicosis [In Process Citation]. Clin Endocrinol (Oxf) 1999; 50: 185-189
10. Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with non-thyroidal illness. J Clin Endocrinol Metab 1994; 78: 1368-1371
11. Meier CA, Maisey MN, Lowry A, Muller J, Smith MA. Interindividual differences in the pituitary-thyroid axis influence the interpretation of thyroid function tests. Clin Endocrinol (Oxf) 1993; 39: 101-107
12. Spencer CA, LoPresti JS, Patel A et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990; 70: 453-460
13. Lecomte P, Lecureuil N, Osorio-Salazar C, Lecureuil M, Valat C. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism. Thyroid 1995; 5: 19-23
14. Roti E, Minelli R, Gardini E, Braverman LE. The use and misuse of thyroid hormone. Endocr Rev 1993; 14: 401-423
15. de Rosa G, Testa A, Maussier ML, Calla C, Astazi P, Albanese C. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with non-toxic goiter. Horm Metab Res 1995; 27: 503-507
16. Faber J, Perrild H, Johansen JS. Bone Gla protein and sex hormone-binding globulin in non-toxic goiter: parameters for metabolic status at the tissue level. J Clin Endocrinol Metab 1990; 70: 49-55
17. Faber J, Gam A, Siersbaek-Nielsen K. Improved sensitivity of serum thyrotropin measurements. Studies on serum sex hormone-binding globulin in patients with reduced serum thyrotropin. Acta Endocrinol (Copenhagen) 1990; 123: 535-540
18. Foldes J, Lakatos P, Zsadanyi J, Horvath C. Decreased serum IGF-1 and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism. EurJ Endocrinol 1997; 136: 277-281
19. Giagulli VA, Vermeulen A. Increased plasma 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide concentration in clinically euthyroid women with suppressed plasma thyrotropin levels: further evidence for generalized tissue overexposure to thyroid hormones in these subjects. J Clin Endocrinol Metab 1992; 74: 1465-1467
20. Tenerz A, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med 1990; 228: 229-233
21. Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P. Serum levels of carboxyterminal cross-linked telopeptide of type 1 collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol (Oxf) 1997; 47: 207-214
22. Engler H, Oettli RE, Riesen WF. Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study. Clin Chim Acta 1999; 289: 159-172
23. Miyakawa M, Tsushima T, Demura H. Carboxy-terminal propeptide of type 1 procollagen (PICP) and carboxy-terminal telopeptide of type 1 collagen (ICTP) as sensitive markers of bone metabolism in thyroid disease. Endocr J 1996; 43: 701-708
24. Isaia GC, Roggia C, Gola D et al. Bone turnover in hyperthyroidism before and after thyrostatic management. J Endocrinol Invest 2000; 23: 727-731
25. Toivonen J, Tahtela R, Laitinen K, Risteli J, Valimaki MJ. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 1998; 138: 667-673
26. Jodar Gimeno E, Munoz-Torres M, Escobar-Jimenez F, Quesada Charneco M, Luna del Castillo JD, Olea N. Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover. Calcif Tissue Int 1997; 61: 370-376
27. Loviselli A, Mastinu R, Rizzolo E et al. Circulating telopeptide type 1 is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 1997; 7: 561-566
28. Martino E, Loviselli A, Velluzzi F et al. Endemic goiter and thyroid function in central-southern Sardinia. Report on an extensive epidemiological survey. J Endocrinol Invest 1994; 17: 653-657
29. Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med 1996; 100: 217-223
30. Sallis JF, Haskell WL, Wood PD et al. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol 1985; 121: 91-106
31. Aghini-Lombardi F, Antonangeli L, Martino E et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999; 84: 561-566
32. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999; 9: 539-543
33. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994; 78: 955-999
34. Langdahl BL, Loft AG, Moller N et al. Skeletal responsiveness to thyroid hormone is not altered at menopause. Bone 1996; 19: 557-564
35. Bartalena L, Martino E, Velluzzi F et al. The lack of nocturnal serum thyrotropin surge in patients with nontoxic nodular goiter may predict the subsequent occurrence of hyperthyroidism. J Clin Endocrinol Metab 1991; 73: 604-608
36. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 1990; 89: 602-608
37. Bregengard C, Kirkegaard C, Faber J et al. Relationships between serum thyrotropin, serum free thyroxine (T4), and 3,5,3′-triiodothyronine (T3) and the daily T4 and T3 production rates in euthyroid patients with multinodular goiter. J Clin Endocrinol Metab 1987; 65: 258-261
38. Dremier S, Coppee F, Delange F, Vassart G, Dumont JE, van Sande J. Clinical review 84: Thyroid autonomy: mechanism and clinical effects. J Clin Endocrinol Metab 1996; 81: 4187-4193
39. Kirkegaard C, Bregengard C. Assessment of the clinically significant TSH response to TRH in patients with nodular goitre. Horm Metab Res 1988; 20: 357-359
40. Romaldini JH, Farah CS, Werner RS, Dall'Antonia Junior RP, Camargo RS. 'In vitro' study on release of cyclic AMP and thyroid hormone in autonomously functioning thyroid nodules. Horm Metab Res 1988; 20: 510-512
41. Hoshino H, Kushida K, Takahashi M et al. Characteristics of biochemical markers in patients with metabolic bone disorders. Endocr Res 1998; 24: 55-64
42. Takahashi M, Kushida K, Kawana K, Hoshino H, Inoue T. Discrimination ability of pyridinoline crosslinks related markers for bone resorption in postmenopause and osteoporosis. Endocr Res 1997; 23: 105-117
43. Takahashi M, Kushida K, Hoshino H, Ohishi T, Inoue T. Evaluation of bone turnover in postmenopause, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption. J Endocrinol Invest 1997; 20: 112-117
44. Yasumizu T, Hoshi K, Iijima S, Asaka A. Serum concentration of the pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen (ICTP) is a useful indicator of decline and recovery of bone mineral density in lumbar spine: analysis in Japanese postmenopausal women with or without hormone replacement. Endocr J 1998; 45: 45-51
45. Brenta G, Schnitman M, Gurfinkiel M et al. Variations of sex hormone-binding globulin in thyroid dysfunction [In Process Citation]. Thyroid 1999; 9: 273-277
46. Hammond GL, Langley MS, Robinson PA. A liquid-phase immunoradiometric assay (IRMA) for human sex hormone binding globulin (SHBG). J Steroid Biochem 1985; 23: 451-460
47. Pasquali R, Vicennati V, Bertazzo D et al. Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism 1997; 46: 5-9